BNTX241220P40000
- 0.15
- 0.000.00%
BioNTech Newsroom
Ryvu Therapeutics Provides an Update on RVU120 Phase II Program
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
BioNTech Analyst Ratings
Wells Fargo Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $170
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
BioNTech SE's Promising Future: Buy Rating Backed by Breakthrough Cancer Therapy and Expansive Pipeline
Strategic Combinations Propel BioNTech's B7-H3 ADC BNT324 Amidst Competitive Landscape: Analyst 'Buy' Rating
Express News | Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 6.54 Million in Common Stocks
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
European Equities Traded in the US as American Depositary Tread Water in Friday Trading
Reported Earlier, Duality Biologics And BioNtech Reveals Interim Results For B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 In Advanced Solid Tumors At ESMO Asia Congress 2024
New stock outlook | Still lagging behind in the PD-1 track, how far behind is Hanseiler's commercialization?
Han's Atezolizumab is in a PD-1 race track with severe homogenization and whether it can be well received by the capital markets after listing?
BioNTech SE ADR Falls Monday, Underperforms Market
Why Is BioNTech SE (BNTX) Among the Best High Growth Healthcare Stocks to Invest In Now?
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech SE (BNTX) Receives a Buy From Morgan Stanley
BMO Capital Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $126
Promising Oncology Developments and Stable COVID-19 Business Drive BioNTech SE's Buy Rating
BioNTech SE (NASDAQ:BNTX) Surges 4.6%; Private Equity Firms Who Own 43% Shares Profited Along With Institutions
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44